latest update:
[TrialBase DB]

trial summary · NCT07676877

Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma

A Phase I Trial of Lymphodepletion Intensification With Low Dose Total Body Irradiation With Dose Expansion for Standard-of-Care Tisagenlecleucel in Patients With Large B-Cell Lymphoma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Diffuse Large B-Cell Lymphoma, sponsored by Nathan Denlinger. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07676877phase PHASE1enrollment 18start 2026-12-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase I trial tests the safety, side effects, and best dose of total body irradiation (TBI) in combination with standard of care lymphodepletion with cyclophosphamide and fludarabine before tisagenlecleucel (Tisa-cel) and how well the combination works in patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). TBI is a common treatment that sends radiation (for example, through x-rays) to the entire body. Lymphodepleting chemotherapy, such as cyclophosphamide and fludarabine, along with TBI helps kill cancer cells in the body and helps prepare the body for the Tisa-cel infusion. Tisagenlecleucel is made using a patient's T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Tisa-cel binds to a protein called CD19, which is found on some leukemia and lymphoma cells. This helps the body's immune system kill cancer cells. Tisa-cel is a type of CAR T-cell therapy. Giving low dose TBI in combination with standard of care lymphodepletion therapy and Tisa-cel may be safe, tolerable, and/or effective in treating patients with relapsed or refractory (R/R) LBCL.

Source record: https://clinicaltrials.gov/study/NCT07676877

Facts

registry idNCT07676877
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionRecurrent Diffuse Large B-Cell Lymphoma
sponsorNathan Denlinger
sponsor classOTHER
enrollment18
start date2026-12-01
primary completion2027-12-31
completion2027-12-31
results postednot reported

Conditions

  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma

Interventions

  • Biospecimen Collection
  • Computed Tomography
  • Cyclophosphamide
  • Fludarabine
  • Leukapheresis
  • Positron Emission Tomography
  • Tisagenlecleucel
  • Total-Body Irradiation

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG, PROCEDURE, RADIATION

Work with this record